We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+8%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$22.5M
Cap. Flow
-$89.9M
Cap. Flow %
-6.81%
Top 10 Hldgs %
48.68%
Holding
85
New
25
Increased
22
Reduced
17
Closed
16

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$62.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$57.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.5M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.4M
5
GPCR icon
Structure Therapeutics
GPCR
+$22.8M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$67.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$65.7M
3
GMED icon
Globus Medical
GMED
+$61.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$53.5M
5
ONC
BeOne Medicines Ltd
ONC
+$49.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$22.6B
$117M 8.86%
1,600,000
+850,000
+113% +$62.7M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$16.1B
$100M 7.6%
900,000
-600,000
-40% -$65.7M
CYTK icon
3
Cytokinetics
CYTK
$10.8B
$79.2M 6.01%
1,500,000
-575,000
-28% -$32M
NARI
4
DELISTED
Inari Medical, Inc. Common Stock
NARI
$63.9M 4.85%
1,550,000
+1,200,000
+343% +$57.6M
ACLX
5
DELISTED
Arcellx
ACLX
$56.4M 4.27%
675,000
– –
GPCR icon
6
Structure Therapeutics
GPCR
$3.4B
$50.5M 3.83%
1,150,000
+590,000
+105% +$22.8M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$46.3M 3.51%
4,000,000
+1,700,000
+74% +$21.4M
ATXS
8
DELISTED
Astria Therapeutics
ATXS
$44M 3.34%
4,000,000
+750,000
+23% +$8.34M
IMTX icon
9
Immatics
IMTX
$1.19B
$42.8M 3.24%
3,750,000
+1,000,000
+36% +$11.8M
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.56B
$41.7M 3.16%
750,000
-1,050,000
-58% -$53.5M
ASND icon
11
Ascendis Pharma A/S
ASND
$16.7B
$37.3M 2.83%
250,000
-500,000
-67% -$67.5M
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$36.4M 2.76%
720,000
-480,000
-40% -$23M
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
$34.8M 2.64%
2,500,000
+1,250,000
+100% +$17.8M
SVRA icon
14
Savara
SVRA
$1.09B
$34.3M 2.6%
8,090,000
+1,600,000
+25% +$7.07M
AGIO icon
15
Agios Pharmaceuticals
AGIO
$2.14B
$33.8M 2.56%
+760,000
New +$34.5M
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.28B
$32.5M 2.46%
825,000
+300,000
+57% +$12.1M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$12B
$28.1M 2.13%
+400,000
New +$33.4M
AVDL
18
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
$26.2M 1.99%
+2,000,000
New +$30.5M
BHVN icon
19
CALL
Biohaven
BHVN
$2.07B
$25M 1.89%
+500,000
New +$19.5M
QURE icon
20
uniQure
QURE
$2.52B
$23.4M 1.78%
4,750,000
– –
JANX icon
21
Janux Therapeutics
JANX
$915M
$22M 1.67%
485,000
-240,000
-33% -$10.4M
BDTX icon
22
Black Diamond Therapeutics
BDTX
$101M
$21.9M 1.66%
5,028,500
+2,928,500
+139% +$15.9M
SLDB icon
23
Solid Biosciences
SLDB
$785M
$19.5M 1.48%
2,800,000
+135,000
+5% +$1.09M
EW icon
24
Edwards Lifesciences
EW
$48.2B
$18.1M 1.38%
+275,000
New +$20M
GILD icon
25
Gilead Sciences
GILD
$167B
$16.8M 1.27%
+200,000
New +$15.3M
1
2 3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Vestal Point Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Vestal Point Capital held 85 positions worth $1.32B, down 1.7% from $1.34B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Vestal Point Capital withdrew a net $89.9M in Q3 2024, closing 16 positions and reducing 17 holdings. Its most notable exit was Globus Medical, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 100% a quarter earlier.

Against the trend, Vestal Point Capital opened a new position in Agios Pharmaceuticals worth $33.8M.

  • Vestal Point Capital's largest Q3 2024 buy was Agios Pharmaceuticals: 760,000 shares worth $33.8M.
  • Vestal Point Capital added most to Insmed in Q3 2024, an estimated $62.7M increase.
  • Vestal Point Capital's biggest Q3 2024 reduction was Ascendis Pharma A/S, cutting an estimated $67.5M.
  • Vestal Point Capital fully exited Globus Medical in Q3 2024, selling an estimated $61.6M.
  • Vestal Point Capital's ten largest holdings make up 49% of its $1.32B portfolio in Q3 2024.
  • Vestal Point Capital opened 25 new positions and closed 16 in Q3 2024.
  • Vestal Point Capital's portfolio value fell 1.7% quarter-over-quarter to $1.32B.

Based on Vestal Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.